tirzepatide lean mass loss Very reassuring data from the first big #zepbound (#tirzepatide/#mounjaro) study for those concerned about (thus concerned about muscle mass) on these meds. Much more fat mass lost, great visceral ( Changes in lean body mass

It means focused evaluation specifically for GLP-1 eligibility

Its important for healing wounds and making new tissue

Elevated insulin levels cause an increase in insulin-like growth factor (IGF-1) and a decrease in insulin-like growth factor-binding protein 3 (IGFBP-3) (182)

Pharmacotherapy of Heart Failure

n=800) key readouts MASH resolution w/ no fibrosis worsening: 62.9% semaglutide vs 34.3% placebo 1-stage fibrosis improvement w/ no MASH worsening: 36.8% vs 22.4% Papers: Resmetirom Semaglutide #MASH #Semaglutide #GLP1 To view or add a comment, sign in More Relevant Posts FDA Approves Boehringer Ingelheims JASCAYD (nerandomilast) for IPF The U.S